The European Medicines Agency’s multinational approach to drug assessment under which new marketing authorization applications are evaluated by teams formed according to expertise rather than by country has proved popular and is now being expanded to the “complex” post-authorization phase. The multinational assessment team (MNAT) concept will be broadened in phases, starting in April. Issues relating to sustainability, knowledge transfer and payment of fees to participating national authorities all have to be considered.
The European Medicines Agency is taking a step-by-step approach to expanding an initiative that for the past four years has enabled national authorities to participate in the initial assessment of new medicines through the involvement of single experts rather than via an entire team.
Until now, the initiative has applied only to procedures under the pre-authorization phase. Starting in April, the agency is expanding...
Center for Biologics Evaluation and Research Director Vinay Prasad said Commissioner Martin Makary wants to release previously inaccessible FDA documents, but previous commissioners have made the same pronouncements only to make little progress.
The Pediatric Advisory Committee will review postmarketing safety for three vaccines and the oncologic drugs panel will consider the return of GSK’s belantamab mafodotin. An FDA notice about a 30 July meeting on Capricor’s deramiocel for Duchenne muscular dystrophy was withdrawn.
Sarepta's rAAVrh74 vector, used in the marketed Duchenne muscular dystrophy gene therapy Elevidys and across the company's limb girdle muscular dystrophy pipeline, earned a platform designation as the lead LGMD candidate prepares for BLA filing.
